These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11118851)

  • 1. New concepts for future control of HIV derived from studies of pathogenesis.
    Gallo RC
    Int J Antimicrob Agents; 2000 Dec; 16(4):421-3. PubMed ID: 11118851
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives in HIV pathogenesis, treatment, and prevention.
    Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):1-3. PubMed ID: 12642030
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-HAART therapy research.
    Gallo RC
    J Hum Virol; 1998; 1(2):67-8. PubMed ID: 10195233
    [No Abstract]   [Full Text] [Related]  

  • 4. The world of HIV and disease, and some new approaches to block it.
    Gallo R
    Bull Mem Acad R Med Belg; 1998; 153(7-9):339-42. PubMed ID: 10100397
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
    Zagury D; Lachgar A; Chams V; Fall LS; Bernard J; Zagury JF; Bizzini B; Gringeri A; Santagostino E; Rappaport J; Feldman M; Burny A; Gallo RC
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3851-6. PubMed ID: 9520456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Tat vaccines.
    Ensoli B; Cafaro A
    Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapeutic interventions targeting HIV interactions with host-associated carbohydrates.
    McReynolds KD; Gervay-Hague J
    Chem Rev; 2007 May; 107(5):1533-52. PubMed ID: 17439183
    [No Abstract]   [Full Text] [Related]  

  • 8. Some recent results on HIV pathogenesis with implications for therapy and vaccines.
    Gallo RC; Garzino-Demo A
    Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1101-4. PubMed ID: 11838957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
    Gallo RC
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
    Moussazadeh M; Hua J; Sidhu MK; Zhao XX; Fitzgibbon JE; Liao MJ; Rashidbaigi A
    Antiviral Res; 1999 Jul; 42(3):177-87. PubMed ID: 10443530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice.
    Sanhadji K; Leissner P; Firouzi R; Pelloquin F; Kehrli L; Marigliano M; Calenda V; Ottmann M; Tardy JC; Mehtali M; Touraine JL
    AIDS; 1997 Jul; 11(8):977-86. PubMed ID: 9223731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of HIV-1 Tat protein biological effects.
    Pugliese A; Vidotto V; Beltramo T; Petrini S; Torre D
    Cell Biochem Funct; 2005; 23(4):223-7. PubMed ID: 15473004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistant HIV: predicting the future.
    Laurence J
    AIDS Read; 2001 Oct; 11(10):485-6. PubMed ID: 11708079
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural anti-HIV antibodies.
    Ward S
    Trends Immunol; 2001 Oct; 22(10):544. PubMed ID: 11574275
    [No Abstract]   [Full Text] [Related]  

  • 16. 4-Phenylcoumarins as HIV transcription inhibitors.
    Bedoya LM; Beltrán M; Sancho R; Olmedo DA; Sánchez-Palomino S; del Olmo E; López-Pérez JL; Muñoz E; San Feliciano A; Alcamí J
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4447-50. PubMed ID: 16137881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway.
    Ott M; Emiliani S; Van Lint C; Herbein G; Lovett J; Chirmule N; McCloskey T; Pahwa S; Verdin E
    Science; 1997 Mar; 275(5305):1481-5. PubMed ID: 9045614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will diverse Tat interactions lead to novel antiretroviral drug targets?
    Harrich D; McMillan N; Munoz L; Apolloni A; Meredith L
    Curr Drug Targets; 2006 Dec; 7(12):1595-606. PubMed ID: 17168834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durhamycin A, a potent inhibitor of HIV Tat transactivation.
    Jayasuriya H; Lingham RB; Graham P; Quamina D; Herranz L; Genilloud O; Gagliardi M; Danzeisen R; Tomassini JE; Zink DL; Guan Z; Singh SB
    J Nat Prod; 2002 Aug; 65(8):1091-5. PubMed ID: 12193009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV regulatory and accessory proteins: new targets for vaccine development.
    Robert-Guroff M
    DNA Cell Biol; 2002 Sep; 21(9):597-8. PubMed ID: 12396601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.